EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants

Kelong Han iD, Hakop Gevorkyan, Jafar Sadik Shaik, Herta Crauwels, Claudia Leemereise, Gilda Bontempo, Beta Win, Vasiliki Chounta, Ciara Seal, Rebecca DeMoor, Ronald D'Amico, William R Spreen und 1 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00781-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Kelong Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Modeling & Simulation, GSK , Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV-1. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cabotegravir + rilpivirine administered via intramuscular gluteal injections is the first complete long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression. The vastus lateralis (lateral) thigh muscle could be a potential alternative site of administration in circumstances such as injection site fatigue, intolerability, or contraindication for gluteal administration. Cabotegravir and rilpivirine pharmacokinetics and participant tolerability were evaluated following single intramuscular injections to the lateral thigh. Healthy adult participants received 4 weeks of daily oral cabotegravir (30 mg) and rilpivirine (25 mg), followed by a 10- to 14-day washout and single 3 mL intramuscular injections of cabotegravir LA 600 mg and rilpivirine LA 900 mg to the lateral thigh. Safety, tolerability, and pharmacokinetics were evaluated through 52 weeks post injection. Pharmacokinetic parameters were estimated using non-compartmental analysis. Fifteen participants (female at birth, n = 6) enrolled. Median age was 33 years. Median weight was 93.6 kg. Median body mass index was 31.4 kg/m 2 . One participant withdrew due to pregnancy after oral dosing before receiving an injection. Plasma concentrations at Weeks 4 and 8 were 15.4- and 5.3-fold above the protein-adjusted 90% inhibitory concentration for cabotegravir and 4.7- and 2.4-fold for rilpivirine, respectively. The most common injection site reactions were pain [28/28 (100%)], induration [15/28 (54%)], and swelling [12/28 (42%)]; 94% were Grade 1 or 2. Cabotegravir and rilpivirine plasma pharmacokinetic profiles observed in this study support further evaluation of thigh administration in target populations of people living with HIV-1. Tolerability of cabotegravir + rilpivirine LA intramuscular lateral thigh injections was similar to gluteal administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHIV-1AdultInfant, NewbornHumansFemaleRilpivirineInjections, IntramuscularQuadriceps MuscleThighPyridonesAnti-Retroviral AgentsDiketopiperazines

Stichwörter der Autor:innen

HIV-1cabotegravirlong-actingpharmacokineticsrilpivirinethigh

Substanzen

RilpivirineAnti-HIV AgentsPyridonesAnti-Retroviral AgentscabotegravirDiketopiperazines

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Modeling & Simulation, GSK , Collegeville, Pennsylvania, USA.
  • California Clinical Trials Medical Group in affiliation with PAREXEL , Glendale, California, USA.
  • Department of Clinical Pharmacology & Pharmacometrics, Janssen Research & Development , Spring House, Pennsylvania, USA.
  • Department of Clinical Pharmacology, Janssen Research & Development , Beerse, Belgium.
  • GSK , Amersfoort, the Netherlands.
  • ViiV Healthcare , Durham, North Carolina, USA.

ORCID-Profile: Kelong Han

Zitieren

APA

Han, K., Gevorkyan, H., Sadik Shaik, J., Crauwels, H., Leemereise, C., Bontempo, G., Win, B., Chounta, V., Seal, C., DeMoor, R., D'Amico, R., Spreen, W. R., & Ford, S. L. (2024). Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00781-23

Vancouver

Han K, Gevorkyan H, Sadik Shaik J, Crauwels H, Leemereise C, Bontempo G, et al. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00781-23

BibTeX
@article{Han2024,
  author = {Han, Kelong and Gevorkyan, Hakop and Sadik Shaik, Jafar and Crauwels, Herta and Leemereise, Claudia and Bontempo, Gilda and Win, Beta and Chounta, Vasiliki and Seal, Ciara and DeMoor, Rebecca and D'Amico, Ronald and Spreen, William R and Ford, Susan L},
  title = {Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00781-23}
}
Kostenlos starten →